hexosomes |
|
Vaxjo ID |
293 |
|
Vaccine Adjuvant Name |
hexosomes |
|
Alternative Names |
Hexosomes are also referred to as non-lamellar inverse hexagonal phase lipid nanoparticles. |
|
Adjuvant VO ID |
VO_0005658
|
|
Description |
Hexosomes are nanostructured lipid carriers with internal inverse hexagonal liquid crystalline phases capable of encapsulating both hydrophilic and hydrophobic vaccine components. |
|
Stage of Development |
Research |
|
Host Species for Testing |
Mouse |
|
Components |
Nanocarriers based on inverse hexagonal liquid crystalline phases (hexosomes) show promising potential as vaccine delivery systems |
|
Structure |
Hexosomes have an internal inverse hexagonal (HII) structure formed by phytantriol and MMG-1 lipids, stabilized by poloxamer 407. |
|
Appearance |
They appear as nanosized, internally structured particles with curved striations under cryo-TEM. |
|
Storage |
Formulations are stable for up to one week at room temperature, with long-term stability not specified. |
|
Preparation |
Prepared by melting and mixing phytantriol and MMG-1 lipids, followed by ultrasonication in PBS with poloxamer 407. |
|
Dosage |
In mice, 200 uL doses were used containing 5 ug antigen and 0.484 mmol/mL immunostimulatory lipids. |
|
Function |
our data demonstrates that hexosomal and liposomal adjuvants activate the immune system via different mechanisms. Our work provides valuable insights into the adjuvant potential of hexosomes and emphasizes that engineering of the supramolecular structure can be used to design adjuvants with customized immunological properties. |
|
Safety |
Hexosomes showed good biocompatibility in vitro and were well tolerated in mice with no signs of toxicity at effective doses. |
| References |
Rodrigues et al., 2018: Rodrigues L, Raftopoulos KN, Tandrup Schmidt S, Schneider F, Dietz H, Rades T, Franzyk H, Pedersen AE, Papadakis CM, Christensen D, Winter G, Foged C, Hubert M. Immune responses induced by nano-self-assembled lipid adjuvants based on a monomycoloyl glycerol analogue after vaccination with the Chlamydia trachomatis major outer membrane protein. Journal of controlled release : official journal of the Controlled Release Society. 2018; 285; 12-22. [PubMed: 29964134].
|
